Download Next Quest with ProSomnus
by Dr. Mark Murphy and Len Liptak
Please complete the form below with your information
to receive instant access to our cover story.
Please complete the form below with your information to receive instant access to the cover story.
Obstructive sleep apnea (OSA) is a public health calamity that requires expert crisis management. Everyone associated with Dental Sleep Medicine (DSM) can recite the key public health and economic statistics that characterize the urgent need for treating more OSA patients.
Facts, figures, and policy abound; DSM continues to struggle with the myriad reasons many physicians remain cautious about oral appliance therapy (OAT). Policy statements on OSA treatment encourage patient preference. Multiple studies agree that 81% of patients prefer OAT. So why do sleep physicians only refer one out of ten patients for OAT?
Finding resolution to this question is the next herculean quest for ProSomnus Sleep Technologies. Over the past few years ProSomnus has aggregated hundreds of data points from physicians boarded in sleep medicine. What have we learned?
Across multiple surveys, 85% of the reservations cited by sleep physicians fall into one of four categories. These four categories are: efficacy, adherence, insurance coverage, and side effects. Let’s dig deeper...
Mark T. Murphy, DDS, D.ABDSM, is an American Board of Dental Sleep Medicine Diplomate and has practiced in the Rochester area for over 35 years. He is the Lead Faculty for Clinical Education at ProSomnus Sleep Technologies, Principal of Funktional Sleep, serves on the Guest Faculty at the University of Detroit Mercy School of Dentistry and as a Regular Presenter at the Pankey Institute. He has served on the Boards of Directors of the Pankey Institute, National Association of Dental Laboratories, the Identalloy Council, the Foundation for Dental Laboratory Technology, St. Vincent DePaul’s Dental Center and the Dental Advisor. He lectures internationally on Leadership, Dental Sleep Medicine, TMD, Treatment Planning, and Occlusion.
Len Liptak is the CEO of ProSomnus® Sleep Technologies. An award-winning executive with expertise growing and operating innovation-oriented businesses, Len is a founding member of ProSomnus, and co-inventor of the company’s flagship product. Len also serves on the company’s Board of Directors. Len earned an MBA from the University of Minnesota’s Carlson School of Management and a BA from Brown University. A lifelong learner, Len has completed executive education programs at John’s Hopkins, and is a member of the Young President’s Organization (YPO).
Featured Sponsor
ProSomnus® Sleep Technologies designs, manufactures and markets FDA Cleared Class II Medical Devices dentists use to treat patients diagnosed with Obstructive Sleep Apnea. ProSomnus Medical Devices are the first, precision oral appliance therapy devices designed to enhance compliance, mitigate side effects and, enable dentists to achieve excellent patient experiences and outcomes. They have been used to treat thousands of patients, with clinical performance that has been validated in randomized controlled trials, retrospective cohort studies, and numerous clinical case reports.